Immune cells from donors take on viruses in transplant patients
NCT ID NCT03665675
First seen Nov 19, 2025 · Last updated Jun 21, 2026 · Updated 26 times
Summary
This early study tests whether immune cells from a donor can safely fight cytomegalovirus (CMV) or adenovirus (AdV) infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-specific T-cells intravenously. The main goals are to check for side effects and see if the treatment can control the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationwide Children's Hospital
RECRUITINGColumbus, Ohio, 43205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
SUSPENDEDColumbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor virus-specific T-cells (CMV or adenovirus)
What this could lead to
If it works, this could offer a new way to control serious viral infections after organ or stem cell transplants, reducing the need for antiviral drugs.
What could go wrong
This is a very early, small pilot study (20 people). It may not work for everyone, and there are risks like graft-versus-host disease or infusion reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.